Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Depression, Depressive Symptoms, Cancer
Phase NA
Enrollment 279
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research study is to evaluate a mobile application (app) for depression treatment called "Moodivate" among cancer survivors. Moodivate was developed by our research team to assist with the treatment of depressed mood. Participants will be randomly assigned to either download the mobile app, "Moodivate", or not. Approximately 2/3 of participants enrolled will receive the mobile app and the remaining 1/3 will not. All participants will complete electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as your experiences using Moodivate and participating in this trial. Participation in this study will take about 12 weeks, beginning today. Participation in this study may help in the treatment of future cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and/or loss of confidentiality. Alternative treatments include contacting your primary care provider or your oncology care team to discuss other available treatments for depressed mood.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Behavioral Activation Therapy App — Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
  • Behavioral: Treatment as Usual — Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 8 weeks with a final follow up at week 12.

Primary Outcomes

  • Change in Depression (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-28
Completion: 2028-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 279 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Collaborators: National Cancer Institute (NCI)
Contact Information
Study Contact:
Jennifer Dahne, Ph.D.
843-876-2280
dahne@musc.edu
Noelle Natale
843-876-9457
natalen@musc.edu
Jennifer Dahne, PhD
843-876-2280
dahne@musc.edu
Medical University of South Carolina
Interventions
  • Behavioral: Behavioral Activation Therapy App — Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
  • Behavioral: Treatment as Usual — Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 8 weeks with a final follow up at week 12.
Study Locations (1 sites)
Medical University of South Carolina, Charleston, South Carolina 29425 United States
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * ILLIC (as determined during manual chart review) * Elevated depressive symptoms, defined as a score of ≥ 8 on the PHQ-9 * Current owner of an iOS- or Android-compatible smartphone * Willingness to utilize a mobile app for the treatment of depressed mood (response of "yes" on yes/no item) * Have a valid e-mail address that is checked regularly or have regular access to text messages (to access follow-up assessments) * English language fluency Exclusion Criteria: * Current suicidal ideation at study screening, defined as a response greater than or equal to 1 on item nine of the PHQ-9 * Severe cognitive impairment that precludes completion of informed consent. For the purposes of assessing eligibility, this criterion is operationalized as: * Prior diagnosis of dementia, or Major Neurocognitive Disorder indicated either via self-report or in the EHR; or * Self-report of cognitive difficulties that impair functional independence
Conditions Traumatic Brain Injury, PTSD - Post Trau...
Phase PHASE2
Enrollment 54
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in current and former first responders with a history of traumatic brain injury. The main questions it aims to answer are: 1. Do cognitive functioning and post-concussive symptoms change after 40 HBOT sessions? 2. Do symptoms of PTSD, depression, and anxiety, or quality of life, change after treatment? Approximately 54 participants will: * Complete medical and behavioral health screening. * Complete cognitive tests and questionnaires before and after treatment. * Receive 40 HBOT sessions at 2.0 atmospheres absolute (ATA), twice daily with at least four hours between sessions. All participants will receive HBOT. There is no comparison group, so the study cannot determine whether HBOT caused any observed changes.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Hyperbaric Oxygen Therapy (HBOT) — Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions at 2.0 atmospheres absolute (ATA). Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions. Cognitive functioning, post-concussive symptoms, psychological symptoms, and quality of life will be assessed before and after treatment.

Primary Outcomes

  • Change in NeuroTrax Global Cognitive Score (Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).)
  • Change in Rivermead Post-Concussion Symptoms Questionnaire (RPQ) score (Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-09-11
Completion: 2027-09-11
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 54 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Summit Hyperbarics and Wellness
Principal Investigators:
  • Steve Wyman, MD (PRINCIPAL_INVESTIGATOR) - Summit Hyperbarics and Wellness
Contact Information
Study Contact:
Troy Nickel, Ph.D.
208-813-9541
tnickel@shwidaho.org
Troy Nickel, Ph.D.
208-813-9541
tnickel@shwidaho.org
Summit Hyperbarics and Wellness
Steve Wyman, MD
Summit Hyperbarics and Wellness
Interventions
  • Drug: Hyperbaric Oxygen Therapy (HBOT) — Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions at 2.0 atmospheres absolute (ATA). Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions. Cognitive functioning, post-concussive symptoms, psychological symptoms, and quality of life will be assessed before and after treatment.
Study Locations (1 sites)
Summit Hyperbarics and Wellness, Boise, Idaho 83716 United States
Eligibility Criteria
Inclusion criteria 1. Adults aged 18 to 75 years. 2. Current or former first responder. 3. Clinically diagnosed with a traumatic brain injury (TBI) and current or persistent post-concussive syndrome, as determined by a qualified health care professional. 4. Participants with comorbid PTSD, depression, or anxiety may be enrolled if all other eligibility criteria are met; these symptoms will be assessed as secondary/exploratory outcomes. 5. Ability to provide informed consent, including the ability to read, understand, and voluntarily sign the informed consent document. 6. Completion of baseline cognitive and psychological assessment measures as part of study enrollment procedures. 7. Presence of clinically significant symptoms resulting in functional impairment in occupational, social, or other key areas of functioning, as determined by clinical evaluation. 8. Sexually active female participants of childbearing potential and sexually active male participants with female partners of childbearing potential must agree to use an acceptable method of contraception for the duration of the study and for 30 days following the final HBOT session. 9. Stable regimen of psychoactive medications (if applicable), including antidepressants, anxiolytics, antipsychotics, stimulants, and mood stabilizers, for a clinically appropriate stabilization period prior to enrollment, as determined by the study physician. Exclusion criteria 1. Untreated pneumothorax 2. History of spontaneous pneumothorax 3. Severe sinus infection 4. Upper respiratory infection 5. Asymptomatic pulmonary lesions on chest x-ray 6. Uncontrollable high fever (greater than 39C) 7. History of chest or ear surgery 8. Congenital spherocytosis 9. Any anemia or blood disorder 10. Any convulsive disorder 11. History of optic neuritis or sudden blindness 12. Middle ear infection 13. Diabetes mellitus (insulin therapy) 14. The participant is pregnant or lactating 15. Nicotine use/substance use/addiction 16. Acute Hypoglycemia 17. Diagnosed Chronic Obstructive Pulmonary Disease (COPD) and Emphysema 18. Presenting with symptoms of cough, congestion, vomiting, diarrhea, or open wounds. 19. Active malignancy 20. Current manic, delusional, or psychotic episodes 21. Serious/current suicidal ideations 22. Severe or unstable physical disorders or major cognitive deficits 23. Inability to attend scheduled clinic visits or comply with study protocols. 24. Treated with HBOT for any reason prior to study enrollment. 25. Non-English speakers 26. History of retinal repair, including laser photocoagulation or retinal detachment surgery. 27. History of middle ear surgery, including tympanoplasty, mastoidectomy, or pressure equalization tube placement. 28. Age greater than 75 years. 29. Use of any of the following medications during the study period: Anti-metabolites (e.g., methotrexate, azathioprine); Chemotherapuetic agents (e.g., cyclophosphamide, cisplatin); Mafenide acetate e.g., Sulfamylon); Disulfiram (e.g, Antabuse); Peripheral vasodilators known to interact with oxygen exposure (e.g., nitroglycerin); and Antibacterial drugs with known HBOT interaction risks.
Conditions Depression, Suicide and Self-harm, Depre...
Phase NA
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Behavioral activation is one such empirically supported intervention. Derived from cognitive-behavioral therapy, a well-established treatment for depression, behavioral activation uses psychoeducation and skill-building to increase an individual's engagement in valued and enjoyable activities (e.g., socializing with family and friends, exercising, participating in a hobby) in order to improve depressive symptoms. Research has shown that behavioral activation is an effective intervention for depressed youth. Additionally, it has been shown as a promising intervention that can be conducted in a brief, virtual format and can be effectively implemented by both trained clinicians and trained, non-licensed interventionists. This project will provide Behavioral Activation for youth (12-17) experiencing depression or suicidal ideation who are currently enrolled in the Youth Depression Suicide Network study in Texas.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Behavioral Activation — All participants will undergo behavioral activation treatment for 8-10 weeks

Primary Outcomes

  • Patient Health Questionnaire 9-modified for adolescents (PHQ-A) (During treatment (every session (week) 1-10))
  • Behavioral Activation for Depression-Short Form (BAD-SF) (During treatment (every session (week) 1-10))
  • Dimensional Anhedonia Rating Scale (DARS) (Baseline (before treatment), post-treatment (session/week 11))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-01
Completion: 2029-12-01
Eligibility
Age: 12 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Baylor College of Medicine
Collaborators: University of Texas
Contact Information
Study Contact:
Emily Bivins, B.S.
713-798-1709
emily.bivins@bcm.edu
Eric Storch, Ph.D.
(713) 798-3579
eric.storch@bcm.edu
Eric Storch, Ph.D.
713-798-3080
eric.storch@bcm.edu
Baylor College of Medicine
Interventions
  • Other: Behavioral Activation — All participants will undergo behavioral activation treatment for 8-10 weeks
Study Locations (1 sites)
Baylor College of Medicine, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Participants must be enrolled in the Texas Youth Depression Suicide Research Network (TX-YDSRN) Registry Study; 2. Be between the ages of 12- 18 or currently enrolled in high school; 3. Have a caregiver that is willing to participate in the program; 4. Be able to commit to weekly sessions for eight weeks; 5. Be currently experiencing depressive symptoms; 6. Be able to participate in telehealth services within the state of Texas; 7. Be willing to provide consent/assent (parents/legally authorized representative (LAR)/guardian or young adult participant, aged 18 or older, must be willing to provide consent; youth, aged 12-17, must be willing to provide assent); 8. Be able to read, write and speak English or Spanish sufficiently to understand the study procedures and provide written informed consent to participate in the study; 9. Be willing to dedicate appropriate time to complete scheduled study assessment and measures and attend intervention sessions (both parent/LAR/guardian and youth) 10. Be able to provide a reliable means of contact. Exclusion Criteria: 1. Have an acute medical or psychological condition(s) that that would, in the judgment of the study medical clinician, make participation difficult or unsafe; 2. Have an acute medical or psychological condition(s) that would result in an inability to accurately complete study requirements (e.g., neurological conditions or significant neurodevelopmental concerns); 3. Have active psychotic or manic symptoms resulting in altered mental status and inability to provide assent or requiring immediate attention and/or higher level of intervention; 4. Have a parent/LAR/guardian who is deemed cognitively unable to provide consent (if youth participant, aged 12-17).
Conditions Autism Spectrum Disorder, Major Depressi...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The current clinical trial is focused on evaluating the efficacy of rTMS for treatment of depression in youth and young adults (hereafter called transition aged youth, TAY) with autism spectrum disorder (ASD). The motivation to undertake the current efficacy study is driven by: (1) the substantial impact of depression on TAY with ASD (based on prevalence and contribution to disability/impairment); (2) lack of evidence-based treatments for depression in autism (there are no current trials rigorously evaluating any treatment for depression, i.e., psychotherapeutic, pharmacotherapeutic, brain stimulation); (3) rTMS has demonstrated efficacy in non-autistic individuals to improve symptoms of depression and may be better tolerated in youth than medication treatment; (4) a prior pilot rTMS study focused on treatment of executive function deficits in autism indicated that high frequency rTMS delivered using a rigorous randomized control trial (RCT) protocol can be feasibly implemented in TAY with autism, is well tolerated (mild to moderate adverse effects and low drop out), and has the potential to improve symptoms of depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Active Bilateral Theta Burst Stimulation — A total of 30 active BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
  • Device: Sham Bilateral Theta Burst Stimulation — A total of 30 sham BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)

Primary Outcomes

  • Change in scores on the 17-item Hamilton Rating Scale for Depression (HRSD-17) (Baseline, end of weeks 1, 2, 3, 4, 5, and 6 of treatment, and at 1-week, 4-weeks and 12-weeks post-treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-01-14
Completion: 2027-01-14
Eligibility
Age: 16 Years – 35 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre for Addiction and Mental Health
Principal Investigators:
  • Stephanie H Ameis, MD, MSC (PRINCIPAL_INVESTIGATOR) - Centre for Addiction and Mental Health
Contact Information
Study Contact:
Viviane Grassmann, PhD
416-535-8501
AutismTMS@camh.ca
Interventions
  • Device: Active Bilateral Theta Burst Stimulation — A total of 30 active BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
  • Device: Sham Bilateral Theta Burst Stimulation — A total of 30 sham BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
Study Locations (1 sites)
Centre for Addiction and Mental Health, Toronto, Ontario M6J 1H4 Canada
Eligibility Criteria
Inclusion Criteria: * Fluent in English * ASD diagnosis confirmed by the clinician/clinical team, and IQ\> or =70 * Able to participate in the informed consent process, provide voluntary informed consent and provide a spontaneous narrative description of the key elements of the study * Clinical stability: determined by a physician, no switch of psychotropic medications or increase in dosage in the last 30 days; no change in other therapeutic interventions in last 30 days * BDI-II score ≥21 that is sustained over a lead-in period of two weeks * Global Assessment of Function (GAF) scores (≤60) that is sustained over a lead-in period of two weeks AND/OR VABS-III below adequate functioning at baseline assessment. Exclusion Criteria: * A history of a DSM-5 substance use disorder (other than tobacco) within the past six months; or a positive baseline urine drug screen * Significantly debilitating medical or neurologic illness, or acute or unstable medical illnesses as determined by study physician * Metal implants or a pace-maker, claustrophobia that would preclude the MRI scan * Actively suicidal (i.e., suicidal ideation with plan and intent) or high risk for suicide as assessed by a study psychiatrist * History of seizures * Taking benzodiazepines at a dose greater or equal to 2mg Lorazepam or any anticonvulsant medication * Prior rTMS treatment * Pregnancy

In-patient SCC TMS

NCT05645575
Recruiting
Conditions Major Depressive Disorder
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The investigators are studying the feasibility, safety, and tolerability of administering accelerated repetitive Transcranial magnetic stimulation(a-rTMS) at frequencies other than standard 10 Hz for in-patient Subjects diagnosed with Major Depressive Disorder. Participants will be recruited from the Resnick Neuropsychiatric Hospital. This study will enroll 30 participants who will undergo up to three brain activity recordings, one MRI scan, one TMS procedure to determine the appropriate frequency and intensity for treatment, daily symptom assessments, and 25 TMS treatments. Participants will be asked to participate for up to 2 weeks.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Open-label TMS — Customized, Open-Label Transcranial Magnetic Stimulation

Primary Outcomes

  • Treatment Efficacy as Measured by Change in Inventory of Depressive Symptoms (Self-Report) at Baseline and Final Visit (2 Weeks (Baseline and Final Visit))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-01
Completion: 2027-02-22
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Los Angeles
Contact Information
Study Contact:
Nikita Vincecruz, BS
310-825-4781
nvincecruz@mednet.ucla.edu
Nikita Vincecruz, BS
UCLA TMS Service and Research Service
Interventions
  • Device: Open-label TMS — Customized, Open-Label Transcranial Magnetic Stimulation
Study Locations (1 sites)
UCLA TMS Service and Research Service, Los Angeles, California 90024 United States
Eligibility Criteria
Inclusion Criteria: 1. All subjects must be between 18-65 years of age. 2. Must have confirmed diagnosis of moderate to severe Major Depressive Disorder (single or recurrent episode) as defined by a HAM-D score of 17 or higher. 3. Failure to respond to a minimum of 2 trials of antidepressant medication 4. Failure to respond from at least two different agent classes 5. Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count). 6. Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration. 7. Subjects are willing and able to adhere to the accelerated treatment schedule. Exclusion Criteria: 8. Are mentally or legally incapacitated, unable to give informed consent 9. Have an infection or poor skin condition over the scalp where the device will be positioned 10. Have increased risk of seizure because of family history, stroke, or currently use medications that lead to increased risk for seizure 11. Diagnosis of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode. 12. Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system. 13. Presence of an implanted magnetic-sensitive medical device present in the body scan, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents. (Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with transcranial magnetic stimulation and MRI.)
Conditions Major Depressive Disorder, Anhedonia
Phase NA
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Anhedonia, the inability to seek-out and experience pleasure, is a common symptom in depression that predicts treatment-resistance and is sometimes exacerbated by first-line antidepressants. In our previous research, we found that anhedonia decreases goal-directed behavior and its related neural activity. In this study, we will investigate target engagement from five-consecutive days of stimulation for participants that are within a unipolar major depressive episode and also have high symptoms of anhedonia.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Device: Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4 — Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic delta-beta coupling in the brain.
  • Device: Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4 — Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic theta-gamma coupling in the brain and is used as an active comparator.
  • Device: Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4 — Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform is randomly selected to be the theta-gamma or delta-beta waveform, but the stimulation is delivered for only a brief period of time of approximately 30 seconds, which is not sufficient to produce a meaningful dose to the brain. This placebo, or sham, stimulation is designed to mimic the sensation of receiving stimulation.

Primary Outcomes

  • Change in coupling strength between prefrontal and posterior cortex (1 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-24
Completion: 2027-07-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Florida State University
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Justin M Riddle, PhD
850-645-2389
jriddle@fsu.edu
Justin M Riddle, PhD
850-645-2389
jriddle@fsu.edu
Florida State University
Justin M Riddle, PhD
Florida State University
Interventions
  • Device: Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4 — Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic delta-beta coupling in the brain.
  • Device: Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4 — Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic theta-gamma coupling in the brain and is used as an active comparator.
  • Device: Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4 — Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform is randomly selected to be the theta-gamma or delta-beta waveform, but the stimulation is delivered for only a brief period of time of approximately 30 seconds, which is not sufficient to produce a meaningful dose to the brain. This placebo, or sham, stimulation is designed to mimic the sensation of receiving stimulation.
Study Locations (1 sites)
Florida State University, Tallahassee, Florida 32306 United States
Eligibility Criteria
Inclusion Criteria: * Between the ages of 18 and 65 * Able to provide informed consent * Have normal to corrected vision * Willing to comply with all study procedures and be available for the duration of the study * Speak and understand English * Mild suicide risk as determined by the Hamilton Depression Rating Scale (HAM-D; less than 3 for the suicidality item) and non-existent or mild risk according to the Depression Symptom Index Suicidality Subscale (DSI-SS). * Patient Health Questionnaire (PHQ-8) greater than or equal to 8 prior to the first session * Snaith Hamilton Pleasure Scale (SHAPS) greater than 33 at the first session * A diagnosis of major depressive disorder on the Mini International Neuropsychiatric Interview for the DSM-V (MINI) Exclusion Criteria: * ADHD (currently under treatment) * Neurological disorders and conditions including, but not limited to history of epilepsy; seizures, except childhood febrile seizures; dementia; history of stroke; Parkinson's disease, multiple sclerosis, cerebral aneurysm; brain tumors * Medical or neurological illness or treatment for a medical disorder that could interfere with study participation. For example, unstable cardiac disease, HIV/AIDS, malignancy, liver or renal impairment * Prior brain surgery * Any brain devices/implants including cochlear implants and aneurysm clips, cardiac pacemaker, or any other implanted electronic device * History of current traumatic brain injury * Pregnancy (for females) * Current severe substance use disorder * Claustrophobia * Based on the use of MRI, additional exclusion/inclusion criteria are considered. Note that many contraindications for stimulation are common with MRI and thus are not repeated. Participants must not have metal in the body that is ferrous, will be required to remove all jewelry, must not have tattoos on the face or neck, must refrain from wearing metal in clothing (underwire) or active gear (possibility of metallic microparticle technology), must not be a metal worker or have an eye injury involving metal. * Anything that in the opinion of the investigator would place the participant at increased risk or preclude the participant's full compliance with or completion of the study * DSM-V diagnosis of present moderate or severe substance use disorder or alcohol use disorder, and past severe substance use disorder or alcohol use disorder, or psychotic disorder within the last 12 months
Conditions Glaucoma, Ocular Hypertension
Phase PHASE4
Enrollment 28
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

a randomized, investigator-blind, interventinal study will compare the effect of benzalkonium-chloride (BAK) preserved and preservative-free (PF) eye drops on conjunctival goblet cells.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Xalatan — Eye drop
  • Drug: Monoprost — Eye drop

Primary Outcomes

  • Goblet cell density (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2021-09-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 28 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Copenhagen University Hospital, Rigshospitalet
Collaborators: Laboratoires Thea
Principal Investigators:
  • Miriam Kolko, MD, PhD (PRINCIPAL_INVESTIGATOR) - Department of ophthalmology, rigshospitalet-Glostrup
Contact Information
Study Contact:
Anne Nagstrup, MD
+4522334504
anne.hedengran.nagstrup@regionh.dk
Miriam Kolko, MD, PhD
miriamk@sund.ku.dk
Anne Nagstrup, MD
22334504
anne.hedengran.nagstrup@regionh.dk
Department of ophthalmology, rigshospitalet.glostrup
Interventions
  • Drug: Xalatan — Eye drop
  • Drug: Monoprost — Eye drop
Study Locations (2 sites)
Department of ophthalmology, rigshospitalet.glostrup, Glostrup Municipality, Danmark 2600 Denmark
Department of drug design and pharmacology, University of Copenhagen, Copenhagen, 2100 Denmark
Eligibility Criteria
Inclusion Criteria: 1. Age \>18years 2. Danish speaking 3. Open angle glaucoma or ocular hypertension 4. Average intraocular pressure equal to or above 22 mmHg Exclusion Criteria: a. history of significant eye diseae (including okular trauma) other than open angle glaucoma and ocular hypertension d. treatment with steroids within the last 3 months from inclusion e. Significant untreated systemic disease such as hypertension, heart failure, diabetes mellitus, stroke, lung disease and autoimmune diseases. Diseases are not reason for exclusion if they are well treated or does not need treatment g. pregnant or breast feeding h. women using unsafe anticonception i. allergy towards trial medication j. patients who cannot cooperate in eye examination k. ocular surface defects l. need for polytherapy in glaucoma treatment
Conditions Hypertension, Old Age
Phase Not Applicable
Enrollment 220
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Observational prospective single-center, non-profit study. Primary objective of the study: To determine if the hypotensive phenotype, defined as one episode of daytime systolic blood pressure (SBP) \<90 mmHg (or two episodes of daytime SBP \<90 mmHg, if mean 24 h SBP is \<125 mmHg) detected at Ambulatory Blood Pressure Monitoring (ABPM) is associated with adverse events at follow up (death, hospitalization, falls, emergency room admission for uncontrolled hypertension, major cardiovascular events)

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Diagnostic tests and questionnaires — Assessment of office blood pressure, orthostatic hypotension, 24-hour ambulatory blood pressure, frailty

Primary Outcomes

  • Incidence of adverse events (At 24 months of follow-up)
  • Prevalence of hypotensive phenotype (At baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-07-15
Completion: 2027-07-15
Eligibility
Age: 75 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituto Auxologico Italiano
Contact Information
Study Contact:
Alessandro Croce, MD
+3902619111
a.croce@auxologico.it
Luca Grappiolo, Dr.
+3902619111
luca.grappiolo@auxologico.it
Alessandro Croce, MD
+390261911
a.croce@auxologico.it
Istituto Auxologico Italiano IRCCS
Interventions
  • Diagnostic Test: Diagnostic tests and questionnaires — Assessment of office blood pressure, orthostatic hypotension, 24-hour ambulatory blood pressure, frailty
Study Locations (1 sites)
Istituto Auxologico Italiano IRCCS, Milan, 20145 Italy
Eligibility Criteria
Inclusion Criteria: * Age ≥ 75 years * Diagnosis of hypertension according to the criteria of the European Society of Cardiology guidelines \[Williams 2018\] * Consent of the patient (or legal representative) to participate in the study Exclusion Criteria: * Refusal of the patient or his/her legal representative * Life expectancy of less than 6 months
Conditions Preeclampsia (PE)
Phase Not Applicable
Enrollment 7473
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia (PE) is a major obstetric complication with severe short- and long-term consequences for both mother and fetus. Early detection is critical to mitigate PE-related morbidity and mortality. Effective screening tools are needed to identify women at risk, enabling timely preventive and therapeutic interventions. Current screening methods primarily target placental biomarkers like sFLT1 and PlGF, which are limited to short-term predictions near symptom onset. Existing first-trimester assessments that incorporate maternal factors and Doppler metrics remain constrained by low sensitivity (\<41%) in compliance with NICE and ACOG guidelines. Recent advancements in cell free RNA (cf-RNA) analysis have revealed potential in first-trimester PE prediction. Findings from the PREMOM study (NCT04990141) established a molecular profile for early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) through cfRNA analysis, culminating in the development of the MaiRa Preeclampsia Test (Maternal Advanced and Innovative Preeclampsia Risk Assessment), which demonstrated high predictive performance for first- and second-trimester screening. The current study hypothesizes that the MaiRa Preeclampsia Test is generalizable, maintaining its predictive accuracy in an independent cohort.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Peripheral blood collection — Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled.

Primary Outcomes

  • Validation of the MaiRa Preeclampsia Test for first-trimester screening (9-14 weeks) of EOPE (From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-02
Completion: 2027-02
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 7473 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: iPremom
Principal Investigators:
  • Carlos Simón, MD, PhD (PRINCIPAL_INVESTIGATOR) - Carlos Simon Foundation
  • Tamara Garrido, PhD (PRINCIPAL_INVESTIGATOR) - iPremom
Contact Information
Study Contact:
Clinical Studies Department
+34 636 260 481
clinicalstudies@ipremom.com
Érika Ortiz Domingo
+34 636 260 481
erika.ortiz@mshareservices.es
Ana Palacios Marqués
+34 965 93 34 60
ana.palacios.marques@gmail.com
Hospital General Universitario Dr. Balmis
Interventions
  • Procedure: Peripheral blood collection — Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled.
Study Locations (11 sites)
Hospital General Universitario Dr. Balmis, Alicante, Alicante 03010 Spain
Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona 08025 Spain
Hospital Comarcal de Vinaròs, Vinaròs, Castellón 12500 Spain
Hospital Universitario Puerta del Mar, Cadiz, Cádiz 11009 Spain
Hospital Universitario A Coruña, A Coruña, La Coruña 15006 Spain
Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid 28850 Spain
Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia 30120 Spain
Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife 38320 Spain
Hospital de Manises, Manises, Valencia 46940 Spain
Hospital Universitario Doctor Peset, Valencia, Valencia 46017 Spain
Eligibility Criteria
Inclusion Criteria: * Signed informed consent approved by the Ethics Committee. * Women ≥18 years of age at consent. * Single gestation pregnancies with first sample collection (T1) possible between 9 and 14 weeks' gestation. Exclusion Criteria: * Active neoplasm. * History of organ or bone marrow transplantation. * Maternal transfusion within 8 weeks before sample collection. * Evidence of early pregnancy loss at consent. * Severe, uncontrolled infections. * Other investigator-assessed risks that could compromise participation or data quality.
Conditions Hypertension, Resistant Hypertension
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Resistant arterial hypertension (RAH) is a complex and multifactorial syndrome, with hyperactivity of the sympathetic nervous system (SNS) and reduction of vagal activity being considered some of the main causes of refractoriness to treatment. Seen from the outside, it resembles a complicated (see lat. "Cum plicate") or complex disease (see lat. "Cum plexus"), Chaotic with the participation of several open systems. For example, in recent years some relationships have been demonstrated between the autonomic nervous systems, synaptic mediators, hormones, inflammatory and immune responses. However, these findings have not been investigated together and systematically. In the present project, we intend to establish and compare, in an integrated way, the clinical alterations present in RAH (resistant and refractory), hemodynamic variables, autonomous activity (sympathetic and baroreflex) and interactions with the neuroimmune-endocrine systems. To this end, we will test the hypothesis that resistant patients have greater damage to the autonomic nervous system (ANS) associated with exacerbated systemic and hormonal inflammatory profile, including SNA mediators (noradrenaline and acetylcholinesterase). This is also intended to determine the behavior (deterministic or chaotic) of the systems evaluated (mentioned above) in volunteers with RAH. Sample and methods: The sample space (calculated) will consist of 72 individuals, being: - 18 refractory hypertensive (HRT); II- 18 resistant hypertensive patients (HRfT); III- 18 controlled hypertensive (1-2 drugs) (CAH); and IV- 18 healthy normotensive individuals. This is a prospective, double-blind study (patient and professional-technician), paired (1 X 4), in which the 72 volunteers will be evaluated by the methods set out below. We will also have the chance to observe whether resistant and refractory hypertension share the same pathophysiological bases and clinical manifestations ("deterministic-isolated or cardiovascular chaos") by analyzing the patterns of cardiovascular variability (MAPA and Holter) (SpaceLabs, USA; DynaMap, Brazil), inflammatory and hormonal mediators (ELISA) in the resistant hypertension - RHT and refratary hypertension - HfRT groups. Central pressure (CP) and arterial stiffness (pulse wave velocity, VOP) (Sphymocor, ATCor, USA) will also be assessed. Healthy normotensive (NT) and controlled hypertension (CAH) will be evaluated in an identical way to control the other groups. Perspectives: The findings will improve the clinical knowledge based on pathophysiology about Resistant Hypertension and, mainly, the bases of pharmacological treatment and with implantable devices (stimulation of baroreceptors and sympathetic denervation) used in this condition.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Interventions / Regimen

  • Other: This is a cross-sectional observational study — There will be no intervention in the study.

Primary Outcomes

  • Blood Pressure (4 weeks)
  • Heart Rate (4 weeks)
  • Level of TNF-α (10 weeks)
  • Level of IL1β, IL-6 (10 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-08-27
Completion: 2026-12-30
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Campinas, Brazil
Collaborators: Fundação de Amparo à Pesquisa do Estado de São Paulo
Contact Information
Study Contact:
TATIANE DE AZEVEDO RUBIO
+55(17)991422510
thatyazevedo@gmail.com
TATIANE DE AZEVEDO RUBIO
+55(17)991422510
thatyazevedo@gmail.com
Tatiane de Azevedo Rubio
Interventions
  • Other: This is a cross-sectional observational study — There will be no intervention in the study.
Study Locations (1 sites)
Tatiane de Azevedo Rubio, Votuporanga, São Paulo 15505185 Brazil
Eligibility Criteria
Inclusion Criteria: * men and women over 35 years of age diagnosed with resistant arterial hypertension (RH), in accordance with the latest international and national guidelines; * be able to understand, verbalize and answer questions; * agree to participate in the study and sign the Informed Consent Form; * after clearly understanding it; * be under regular follow-up at the UNICAMP Cardiovascular Pharmacology outpatient clinic for at least six months; * have proven adherence to non-pharmacological and pharmacological treatment; * women in the reproductive phase must be using a proven effective contraceptive method. Exclusion Criteria: * clinical history or clinical symptoms of heart failure; * patients with dilated cardiomyopathies, valvular heart disease, pericardial disorders; * patients with cerebrovascular disease or peripheral arterial disease, nephropathies, liver diseases, smoking, autoimmune diseases and use of illicit substances; * any abnormal condition that may interfere with the results of the study or the health of the volunteer, as judged by the researcher; * women who are pregnant or intend to become pregnant; * current participation in another investigative study; * major depression or other relevant psychiatric disorders.
Conditions Hypertension, Pre-eclampsia
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the study is to assess the accuracy of the automatic oscillometric BP measuring device at the brachial level, the WITHINGS BPM Pro 2, in pregnancy and pre-eclampsia

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: Blood pressure measurement — The patient will be measured alternatively with a reference mercury sphygmomanometer (four times) and the device under study (3 times)

Primary Outcomes

  • Blood pressure measurement performace evaluation per measure (5 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-11
Completion: 2026-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Withings
Contact Information
Study Contact:
Inès Bedouda
0141460460
clinical-trials@withings.com
Parounak ZELVEIAN, Professor
374-10-530572
zelveian@hotmail.com
N2
Interventions
  • Device: Blood pressure measurement — The patient will be measured alternatively with a reference mercury sphygmomanometer (four times) and the device under study (3 times)
Study Locations (1 sites)
N2, Yerevan, Armenia 0002 Armenia
Eligibility Criteria
Inclusion Criteria: * Patient older than 18 years; * Known pregnancy, in second or third trimester of pregnancy ( \> 3 months); * Patient normotensive, hypertensive or in preeclampsia; * Patient who signed the informed consent form; * Patient followed-up at site (in-patient or out-patient); * Patient with arm circumference between 22 cm and 42 cm. Exclusion Criteria: * Patient unable to give a consent or understand properly protocol information; * Patient suffering from arrhythmia; * Patient with poor quality of Korotkov sounds; * Patient for whom K5 sounds are absent; * Patient wearing an implantable electric medical device (pacemaker,…); * Patient with both upper arms suffering from open wound and/or damaged skin.
Conditions Hypertension, Retroperitoneal Disease
Phase NA
Enrollment 246
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to evaluate the efficacy and safety of laparoscopic renal artery nerve blockade surgery in patients with retroperitoneal diseases complicated by hypertension. The study aims to address the following two questions: 1. Can laparoscopic renal artery perivascular nerve blockade reduce postoperative blood pressure and decrease the dependence on antihypertensive medications in patients with retroperitoneal diseases and hypertension? 2. What is the safety profile of the procedure, and does it lead to any complications? The researchers will randomly assign patients to the experimental group and the control group. The experimental group will undergo surgery related to the primary disease in addition to laparoscopic renal artery perivascular nerve blockade, while the control group will only receive surgery related to the primary disease. This design allows for a comparison of the effects of renal artery perivascular nerve blockade on postoperative blood pressure. Participants will: 1. Patients will undergo either surgery related to the primary disease combined with renal artery perivascular nerve blockade, or surgery related to the primary disease alone. 2. For the three months following surgery, the antihypertensive medication regimen will remain unchanged from the preoperative plan. At the end of the three-month period, patients will visit the hospital for 24-hour ambulatory blood pressure monitoring.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: laparoscopic renal artery perivascular nerve blockade — 1. When only the main renal artery is present: The complete dissection of the renal artery should be performed in the distal 2/3 portion, close to the renal hilum. The connective tissue and nerve tissue within a 1 cm radius from the center of the renal artery lumen must be completely separated (using instruments such as an ultrasonic scalpel or monopolar hook, etc.). The length of the dissected renal artery should be at least 0.5 cm, forming a dissection ring. 2. When accessory renal arteries are present: In addition to the main renal artery meeting the aforementioned standards, the accessory renal arteries must also be dissected. The radius of the dissection ring should be 0.7 cm, with a length ranging from 0.3 to 0.5 cm. 3. When renal polar arteries are present: Dissection may be performed appropriately based on the surgical conditions. 4. The prerequisite is to ensure the safety of the surgery, specifically the safe resection of the primary lesion.
  • Procedure: surgery related to the primary disease — The surgeries related to the primary disease include laparoscopic partial nephrectomy, laparoscopic adrenalectomy, and other similar procedures.

Primary Outcomes

  • The blood pressure values at 3 months post-surgery. (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-01
Completion: 2026-12-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 246 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ruijin Hospital
Contact Information
Study Contact:
Xu
13901734568
xdf12036@rjh.com.cn
Ruijin hospital
Interventions
  • Procedure: laparoscopic renal artery perivascular nerve blockade — 1. When only the main renal artery is present: The complete dissection of the renal artery should be performed in the distal 2/3 portion, close to the renal hilum. The connective tissue and nerve tissue within a 1 cm radius from the center of the renal artery lumen must be completely separated (using instruments such as an ultrasonic scalpel or monopolar hook, etc.). The length of the dissected renal artery should be at least 0.5 cm, forming a dissection ring. 2. When accessory renal arteries are present: In addition to the main renal artery meeting the aforementioned standards, the accessory renal arteries must also be dissected. The radius of the dissection ring should be 0.7 cm, with a length ranging from 0.3 to 0.5 cm. 3. When renal polar arteries are present: Dissection may be performed appropriately based on the surgical conditions. 4. The prerequisite is to ensure the safety of the surgery, specifically the safe resection of the primary lesion.
  • Procedure: surgery related to the primary disease — The surgeries related to the primary disease include laparoscopic partial nephrectomy, laparoscopic adrenalectomy, and other similar procedures.
Study Locations (1 sites)
Ruijin hospital, Shanghai, China
Eligibility Criteria
Inclusion Criteria: * Renal artery diameter ≥ 4 mm, length ≥ 20 mm. * Age between 18 and 75 years, male or female. * Scheduled to undergo laparoscopic surgery: The patient has a clear diagnosis of adrenal tumor, early-stage renal malignancy, renal cyst, etc., and meets the surgical indications recommended by guidelines or relative surgical indications but has a strong willingness for surgery. The patient requires surgery (such as laparoscopic partial adrenalectomy, laparoscopic unilateral adrenalectomy, laparoscopic partial nephrectomy, laparoscopic renal cyst decapitation, etc.) and meets the surgical conditions. * A clear diagnosis of hypertension: Either the patient has never used antihypertensive medications, with in-office blood pressure ≥ 140/90 mmHg and \< 180/110 mmHg, or 24-hour daytime ambulatory blood pressure ≥ 135/85 mmHg and \< 170/105 mmHg. Alternatively, the patient has been diagnosed with hypertension and has been taking antihypertensive medications for at least 4 weeks. * Estimated glomerular filtration rate (eGFR) ≥ 45 ml/min/1.73 m². * The patient is willing and able to comply with the study protocol, provide written informed consent, and agrees to participate in follow-up assessments. Exclusion Criteria: * Renal artery abnormalities: Hemodynamic or anatomical stenosis (≥50%) of one renal artery; post-renal artery balloon angioplasty or stent placement; * Cardiovascular risk factors: Including myocardial infarction, unstable angina, or cerebrovascular events within the past 6 months; extensive atherosclerosis with intravascular thrombosis or unstable plaques; and significant hemodynamic changes due to heart valve disease; * History of similar surgeries: Such as previous renal sympathetic nerve ablation via catheter; * Other severe organic diseases; * Participation in other clinical studies; * Investigator's judgment: The investigator determines that, based on medical expertise, the patient is unsuitable for participation in the study.